NeuroDiscovery makes market debut
15 August, 2005 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
German Relenza deal shows we're right: Biota
15 August, 2005 by Helen SchullerMelbourne-based biopharma Biota Holdings (ASX:BTA) has confirmed that the German government has ordered 1.7 million packs of its flu vaccine Relenza, but CEO Peter Molloy said he still believed that licensee GlaxoSmithKline was not doing enough to promote the drug, .
Phylogica and PharmAust sign partnering deal
15 August, 2005 by Ruth BeranPhylogica (ASX:PYC) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a collaborative partnership deal to develop peptide drugs.
Polartechnics EGM nixes Opara resolutions
15 August, 2005 by Ruth BeranAn extraordinary general meeting of Polartechnics (ASX:PLT) shareholders, requisitioned by the company's former interim chairman Richard Opara, has voted against each of the resolutions he put forward.
Psivida in talks to acquire US drug delivery company
15 August, 2005 by Ruth BeranTrading of shares in Perth-based nano-biotech company Psivida (ASX:PSD) resumed trading today, after the company revealed that it was in negotiations to acquire an as yet unnamed US based specialised drug delivery company.
Metabolic pain drug meets trial milestones
15 August, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has received a go-ahead to progress its painkiller ACV1 to the second part of its phase I clinical trial dosing in humans.
WA forum looks to the future of agbiotech
12 August, 2005 by Cristy BurneThe Western Australian branch of industry association AusBiotech has held a forum to examine the issues facing agricultural biotechnology in the state, and the challenges that must be faced if it is to move forward.
Polartechnics EGM to proceed despite Opara's request to postpone
11 August, 2005 by Ruth BeranA Polartechnics (ASX:PLT) extraordinary general meeting (EGM) requisitioned by the company's former interim chairman Richard Opara will be held in Sydney this Friday, despite the company receiving a letter from him on August 8 proposing to postpone the meeting.
Relenza order report leaves Biota mystified
11 August, 2005 by Iain ScottBiota Holdings (ASX:BTA) has backed as "accurate" a newspaper report that Germany has placed an order of more than AUD$100 million for Relenza, the anti-flu drug developed by Biota and commercialised by GlaxoSmithKline.
C3 raises $10m
11 August, 2005 by Ruth BeranPerth-based Clinical Cell Culture (C3, ASX:CCE) has placed 28.6 million new fully paid ordinary shares worth AUD$10 million with Australian institutional and sophisticated investors.
NZ's AgVax acquired by Dutch firm Intervet
11 August, 2005 by Helen SchullerNew Zealand-based animal vaccine specialist AgVax Developments has been taken over by Intervet, a business unit of Dutch healthcare giant Akzo Nobel.
EvoGenix lists at 20 per cent premium
11 August, 2005 by Ruth BeranAntibody therapeutic developer EvoGenix (ASX:EGX) listed today on the Australian Stock Exchange at AUD$0.30, 20 per cent above its issue price of AUD$0.25.
Select Vaccines out-licenses hepatitis A diagnostic test
10 August, 2005 by Ruth BeranSelect Vaccines (ASX:SLT) has licensed the manufacture, global marketing and distribution of its rapid hepatitis A diagnostic technology to US-based Rapid Medical Diagnostic (RMD), but has kept the distribution rights for the test in Australia and New Zealand.
Avexa ends year with two years' cash in the bank
10 August, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has finished its first financial year of operation with AUD$15.7 million in the bank -- enough operating cash for two years, according to CEO Julian Chick .
Apollo claims competitive advantage
10 August, 2005 by Ruth BeranRecently listed Sydney biopharma Apollo Life Sciences (ASX:AOP) has claimed that its human-expressed vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels, performs five times better in an international proliferation test than a leading competitor's protein and the World Health Organisation's (WHO) protein standard.
